Mitral valve repair in dogs using an ePTFE chordal implantation device: a pilot study

Borgarelli, Michele; Lanz, Otto I.; Pavlisko, N.; Abbott, Jonathan A.; Menciotti, Giulio; Aherne, Michael; Lahmers, Sunshine; Lahmers, Kevin; Gammie, James S.

doi:10.1016/j.jvc.2017.03.002

Cited by 16 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clopidogrel may be efficacious for arterial thromboprophylaxis in dogs. [171][172][173][174][175] However, insufficient evidence is available to judge the efficacy of clopidogrel for prevention of venous thrombosis in dogs.…”

Section: Rationalementioning

confidence: 99%

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Swann

Garden

Fellman

et al. 2019

Veterinary Internal Medicne

187

View full text Add to dashboard Cite

Immune‐mediated hemolytic anemia (IMHA) causes severe anemia in dogs and is associated with considerable morbidity and mortality. Treatment with various immunosuppressive and antithrombotic drugs has been described anecdotally and in previous studies, but little consensus exists among veterinarians as to the optimal regimen to employ and maintain after diagnosis of the disease. To address this inconsistency and provide evidence‐based guidelines for treatment of IMHA in dogs, we identified and extracted data from studies published in the veterinary literature. We developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria, explanation of treatment regimens, and validity of statistical methods. In combination with our clinical experience and comparable guidelines for humans afflicted with autoimmune hemolytic anemia, we used the conclusions of this process to make a set of clinical recommendations regarding treatment of IMHA in dogs, which we refined subsequently by conducting several iterations of Delphi review. Additionally, we considered emerging treatments for IMHA in dogs and highlighted areas deserving of future research. Comments were solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted for publication. The resulting document is intended to provide clinical guidelines for management of IMHA in dogs. These guidelines should be implemented pragmatically, with consideration of animal, owner, and veterinary factors that may vary among cases.

show abstract

Section: Rationalementioning

confidence: 99%

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Swann

Garden

Fellman

et al. 2019

Veterinary Internal Medicne

187

View full text Add to dashboard Cite

show abstract

“…In dogs, 11 papers (LOE 3, Good), and 6 papers (LOE 3, Fair), suggest efficacy of clopidogrel. Of these publications, 10 papers suggest in vivo efficacy against provoked arterial thrombosis, while 7 publications suggest clopidogrel has significant platelet inhibitory effects ex vivo using tests such as platelet aggregometry.…”

Section: Pico Question: Clopidogrel Therapymentioning

confidence: 99%

“…In vitro tests suggest that 1.1 mg/kg PO q24h causes inhibition of ADP‐dependent platelet inhibition in dogs, while 4 mg/kg POq24h after a 10 mg/kg loading dose provides protection against arterial thrombosis provoked by bioprosthesis implantation . In coronary or femoral arterial thrombosis models, doses of 0.5–2.0 mg/kg IV provide protection from thrombosis …”

Section: Pico Question: Clopidogrel Therapymentioning

confidence: 99%

Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 3—Defining antithrombotic protocols

Blais

Bianco

Goggs

et al. 2019

J Vet Emergen Crit Care

View full text Add to dashboard Cite

Objectives:To systematically examine the evidence for use of a specific protocol (dose, frequency, route) of selected antithrombotic drugs, in comparisons to no therapy or to other antithrombotic therapies, to reduce the risk of complications or improve outcomes in dogs and cats at risk for thrombosis. Design: Standardized, systematic evaluation of the literature, categorization of relevant articles according to level of evidence (LOE) and quality (Good, Fair, or Poor), and development of consensus on conclusions via a Delphi-style survey for application of the concepts to clinical practice. Settings: Academic and referral veterinary medical centers. Results: Databases searched included Medline via PubMed and CAB abstracts. Eight different antithrombotic drugs were investigated using a standardized Patient, Intervention, Comparison, Outcome (PICO) question format both for dogs and cats, including aspirin, clopidogrel, warfarin, unfractionated heparin (UFH), dalteparin, enoxaparin, fondaparinux, and rivaroxaban, generating a total of 16 worksheets. Most studies identified were experimental controlled laboratory studies in companion animals (LOE 3) with only four randomized controlled clinical trials in companion animals (LOE 1). Conclusions:Overall, evidence-based recommendations concerning specific protocols could not be formulated for most antithrombotic drugs evaluated, either because of the wide range of dosage reported (eg, aspirin in dogs) or the lack of evidence in the current literature. However, clopidogrel administration in dogs and cats at risk of arterial thrombosis, notably in cats at risk of cardiogenic thromboembolism, is supported by the literature, and specific protocols were recommended. Comparably, aspirin should not be used as a sole antithrombotic in cats with cardiomyopathy. Using the available safety profile information contained in the literature, the panel reached consensus on suggested dosage schemes for most antithrombotics. Significant knowledge gaps were highlighted, which will hopefully drive novel research.

show abstract

“…Klopidogrel, ADP reseptörünün geri dönüşümsüz inhibitörü bir ön ilaç olup, yapılan çalışmalarla köpeklerde antitrombotik etkinliği ortaya konmuştur. [31][32][33][34][35] Çalışmalarda; kullanılan köpekler, çalışma modeli ve trombotik uyaranlara bağlı olarak bildirilen dozlar önemli ölçüde değiş mektedir. Ağız yolu ile günlük en düşük etkili doz 0,21 mg/kg olarak belirtilirken, farklı model sistemlerinde Dİ yolla 10 mg/kg'a kadar olan dozların arteriyel trombozun önlenmesinde devamlı etkinlik sağlamadığı rapor edilmiştir.…”

Section: Klopidogrelunclassified

“…34 Klopidogrel 10 mg/kg yükleme dozundan sonra günde 1 kez 4 mg/kg dozda ağızdan verildiğinde, deneysel oluşturulan arteriyel trombozise karşı koruma sağlamıştır. 33 Koroner veya femoral arter tromboz modellerinde, D0, 0.5-2.0 mg/kg klopidogrelin trombozu önlediği bildirilmiştir. 35 Köpeklerde venöz trombozisde klopidogrelin etkinliği veya kullanılmaması gerektiği ile ilgili veri bulunmamaktadır.…”

Section: Klopidogrelunclassified

Use of Antithrombotic Drugs in Cats and Dogs

Kütahya¹,

Traş²

2019

Turkiye Klinikleri J Vet Sci

View full text Add to dashboard Cite

Mitral valve repair in dogs using an ePTFE chordal implantation device: a pilot study

Cited by 16 publications

References 42 publications

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 3—Defining antithrombotic protocols

Use of Antithrombotic Drugs in Cats and Dogs

Contact Info

Product

Resources

About